Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist
Top Cited Papers
- 21 September 2003
- journal article
- letter
- Published by Springer Nature in Nature Medicine
- Vol. 9 (10) , 1323-1326
- https://doi.org/10.1038/nm935
Abstract
The polycystic kidney diseases (PKDs) are a group of genetic disorders causing significant renal failure and death in children and adults. There are no effective treatments. Two childhood forms, autosomal recessive PKD (ARPKD) and nephronophthisis (NPH), are characterized by collecting-duct cysts1,2. We used animal models orthologous to the human disorders to test whether a vasopressin V2 receptor (VPV2R) antagonist, OPC31260, would be effective against early or established disease. Adenosine-3′,5′-cyclic monophosphate (cAMP) has a major role in cystogenesis3,4, and the VPV2R is the major cAMP agonist in the collecting duct5,6. OPC31260 administration lowered renal cAMP, inhibited disease development and either halted progression or caused regression of established disease. These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered.Keywords
This publication has 25 references indexed in Scilit:
- Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosisNature Genetics, 2003
- Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cellsNature Genetics, 2003
- Polycystin-2 is an intracellular calcium release channelNature Cell Biology, 2002
- The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like proteinNature Genetics, 2002
- Polycystin-1 transforms the cAMP growth-responsive phenotype of M-1 cellsKidney International, 2001
- The Basic and Clinical Pharmacology of Nonpeptide Vasopressin Receptor AntagonistsAnnual Review of Pharmacology and Toxicology, 2001
- cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathwayKidney International, 2000
- The Polycystic Kidney Disease-1 Protein, Polycystin-1, Binds and Activates Heterotrimeric G-Proteinsin VitroBiochemical and Biophysical Research Communications, 1998
- Somatic Inactivation of Pkd2 Results in Polycystic Kidney DiseaseCell, 1998
- The clinical utility of renal concentrating capacity in polycystic kidney diseaseKidney International, 1989